Learn about Lyme disease and the ZEUS Borrelia MTTT™ on Lifetime Network's Access Health Series September 25th at 7:30am ET*

Learn about Lyme disease and the ZEUS Borrelia MTTT™ on Lifetime Network's Access Health Series September 25th at 7:30am ET*

Be sure to tune in to Lifetime network’s Access Health on September 25th, 2020 which will provide useful information on Lyme disease, with an emphasis on symptoms and the importance of testing featuring the ZEUS Borrelia Modified Two-Tiered Testing (MTTT™) algorithm.

Access Health is a TV series that works to educate viewers on the latest advances in medicine, nutrition and fitness.  Top physicians provide insight relating to the latest health care developments allowing the audience to become better-educated advocates for their own health.

Watch as Dr. Raymond Dattwyler, M.D. discusses how ZEUS Borrelia MTTT™ is helping clinical laboratories simplify Lyme testing processes and improving detection of early Lyme disease, all while reducing turnaround time, providing patients access to the treatment they need. 

 

Faster. Easier. More Accurate.

The advantages of implementing ZEUS Borrelia MTTT™ are clear.  The all-ELISA algorithm is the simple, sensitive and specific alternative that is changing the game in Lyme disease testing.

 

 

ZEUS Borrelia MTTT™ Advantages

• Reduces the number of missed clinically positive patient samples, especially in early Lyme (stage 1 and 2)
• Removes the burden of Western blots and subjectivity of reading and interpreting
• Enables simple and flexible first-tier and second-tier testing in-house
• Improves overall lab workflow and cost efficiencies, eliminating send-outs
• Improves turnaround time

 

 

ZEUS Borrelia MTTT™ is a simpler, more cost effective, faster and better way to more accurately detect Lyme disease than using immunoblots. This updated algorithm detected up to 30% more clinically confirmed positive patients in acute early Lyme disease, the critical time to correctly identify and treat!

If you are still running Lyme disease immunoblots in your laboratory, take a look at the clinical data to see how ZEUS Borrelia MTTT™ improves detection in early Lyme disease.

With the only FDA-approved Modified Two-Tiered Testing algorithm available, let us help you improve your ability to provide your physicians the right answers their patients sorely need!

 

Simplify your testing. Contact ZEUS today!

Visit zeuslyme.com to learn more.

 

Best,

The ZEUS Scientific Team

 

*check your local TV listings for your time zone

Back Share